IBI-Ag is developing technology at the intersection of three of the most consequential needs in agriculture: the global race for food security , a major shift toward biological crop protection and the application of artificial intelligence to life science discovery.
Our Investors
Market Context
The global bioinsecticide market is growing rapidly, driven by increasing regulatory restrictions on synthetic pesticides, rising demand from retailers and consumers for residue-free produce, and growing awareness of the ecological costs of conventional pest management.
IBI-Ag is positioned to address this market with differentiated technology — a proprietary platform capable of generating novel bioinsecticide proteins faster, against a broader range of targets, and with superior commercial attributes compared to existing biological solutions.
Competitive Differentiation
First-mover advantage
IBI -Ag is the first company to demonstrate nanobody efficacy in the field and to the best of our knowledge, IBI-Ag operates the world’s first AI-driven de novo protein design platform purpose-built for bioinsecticides
IP Protected data base of targets and leads
A curated, validated bank of insect protein targets and insecticidal leads limiting competitors freedom to operate
Dual-platform architecture
Two complementary discovery engines provide pipeline breadth and resilience
Compressed timelines
~4 months from target to candidate vs. ~12 months for conventional approaches
Lab in the loop
In-house production analysis and validation capbilities
Superior product attributes
Novel mode of action, long shelf life, greater stability
Corporate Structure & Backing
IBI-Ag was founded by The Trendlines Group (SGX: 42T / OTCQX: TRNLY),
a publicly listed venture builder and investor in agrifood and medtech innovation,
together with scientific co-founders Prof. Amir Ayali and Dr. Rony Oren Benaroya.
The company is additionally supported by the Israel Innovation Authority.